Alliance Resource Partners, L.P. (ARLP) is priced at $3.88 after the most recent trading session. At the very opening of the session, the stock price was $3.87 and reached a high price of $4.09, prior to closing the session it reached the value of $3.76. The stock touched a low price of $3.6.

Alliance Resource Partners, L.P. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $19.68 on 05/03/19, with the lowest value was $2.70 for the same time period, recorded on 04/01/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Alliance Resource Partners, L.P. shares are logging -80.28% during the 52-week period from high price, and 43.70% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $2.70 and $19.68.

The companys shares, operating in the sector of basic materials managed to top a trading volume set approximately around 1.12 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Alliance Resource Partners, L.P. (ARLP) recorded performance in the market was -64.14%, having the revenues showcasing -58.01% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 492.06M, as it employees total of 3602 workers.

During the last month, 1 analysts gave the Alliance Resource Partners, L.P. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 7.29, with a change in the price was noted -6.34. In a similar fashion, Alliance Resource Partners, L.P. posted a movement of -62.04% for the period of last 100 days, recording 910,453 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for ARLP is recording 0.63 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.61.

Raw Stochastic average of Alliance Resource Partners, L.P. in the period of last 50 days is set at 23.94%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 68.71%. In the last 20 days, the companys Stochastic %K was 55.05% and its Stochastic %D was recorded 46.16%.

Bearing in mind the latest performance of Alliance Resource Partners, L.P., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -64.14%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -66.72%, alongside a downfall of -79.69% for the period of the last 12 months. The shares increased approximately by 2.69% in the 7-day charts and went down by 14.12% in the period of the last 30 days. Common stock shares were lifted by -58.01% during last recorded quarter.

Read more:

Alliance Resource Partners, L.P. (ARLP) is primed for evolution with the beta value of 1.60 - The InvestChronicle

Lets start up with the current stock price of Camden Property Trust (CPT), which is $88.07 to be very precise. The Stock rose vividly during the last session to $88.5 after opening rate of $87.65 while the lowest price it went was recorded $85.81 before closing at $88.88.

Camden Property Trust had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $120.73 on 02/24/20, with the lowest value was $62.48 for the same time period, recorded on 03/23/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Camden Property Trust shares are logging -27.05% during the 52-week period from high price, and 40.96% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $62.48 and $120.73.

The companys shares, operating in the sector of financial managed to top a trading volume set approximately around 1.62 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Camden Property Trust (CPT) recorded performance in the market was -16.99%, having the revenues showcasing -20.55% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 8.90B, as it employees total of 1650 workers.

During the last month, 13 analysts gave the Camden Property Trust a BUY rating, 2 of the polled analysts branded the stock as an OVERWEIGHT, 4 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 100.07, with a change in the price was noted -22.62. In a similar fashion, Camden Property Trust posted a movement of -20.44% for the period of last 100 days, recording 856,626 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for CPT is recording 0.70 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.70.

Raw Stochastic average of Camden Property Trust in the period of last 50 days is set at 43.93%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 85.47%. In the last 20 days, the companys Stochastic %K was 84.11% and its Stochastic %D was recorded 79.47%.

Considering, the past performance of Camden Property Trust, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -16.99%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -22.37%, alongside a downfall of -12.27% for the period of the last 12 months. The shares increased approximately by 1.23% in the 7-day charts and went down by 6.06% in the period of the last 30 days. Common stock shares were lifted by -20.55% during last recorded quarter.

Original post:

Camden Property Trust (CPT) is primed for evolution with the beta value of 0.78 - The InvestChronicle

Diversified Healthcare Trust (DHC) is priced at $3.11 after the most recent trading session. At the very opening of the session, the stock price was $3.12 and reached a high price of $3.16, prior to closing the session it reached the value of $3.22. The stock touched a low price of $2.94.

Diversified Healthcare Trust had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $9.85 on 10/23/19, with the lowest value was $2.00 for the same time period, recorded on 03/19/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Diversified Healthcare Trust shares are logging -68.42% during the 52-week period from high price, and 55.50% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $2.00 and $9.85.

The companys shares, operating in the sector of financial managed to top a trading volume set approximately around 2.83 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Diversified Healthcare Trust (DHC) recorded performance in the market was -61.80%, having the revenues showcasing -60.83% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 739.13M, as it employees total of 600 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 5.98, with a change in the price was noted -4.44. In a similar fashion, Diversified Healthcare Trust posted a movement of -58.81% for the period of last 100 days, recording 2,045,290 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for DHC is recording 1.28 at the time of this writing. In addition, long term Debt to Equity ratio is set at 1.28.

Raw Stochastic average of Diversified Healthcare Trust in the period of last 50 days is set at 18.35%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 63.58%. In the last 20 days, the companys Stochastic %K was 65.33% and its Stochastic %D was recorded 55.79%.

Considering, the past performance of Diversified Healthcare Trust, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -61.80%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -67.10%, alongside a downfall of -59.95% for the period of the last 12 months. The shares increased approximately by 2.04% in the 7-day charts and went up by 18.70% in the period of the last 30 days. Common stock shares were lifted by -60.83% during last recorded quarter.

Read more from the original source:

Diversified Healthcare Trust (DHC) is primed for evolution with the beta value of 0.98 - The InvestChronicle

However, with the necessity of social distancing becoming the norm rather than the exception for the foreseeable future, PR professionals need to reimagine how they are going to effectively interact with the public and media to ensure that their clients' messaging reaches the intended target audience.What will remain the sameThe PR industry employs several tactics to disseminate their clients' messaging into the marketplace. These include:

"Previously, it was very easy to do so," says Schneider. "All PR firms had to do was to put on an event that would appeal to their audience, introduce them to the brand, give them goodie bags and free food and drinks; the invitees would be all too happy to post on social media about their experiences."

"However, it's tough to generate this same type of interaction between your brand and customers using digital. This means that PR firms will need to think out of the box in terms of creating the same type of buzz around a brand," adds Schneider.

The COVID-19 pandemic has made us all incredibly vulnerable. However, it is from this place of vulnerability that PR professionals will be able to innovate their industry to make it better than it was before.

The Digital School of Marketing is an online provider of accredited digital marketing education, which will allow you to get an edge over your competitors.

To find out more, visit http://www.digitalschoolofmarketing.co.za. You can also follow the Digital School of Marketing on Facebook, Twitter or on Instagram.

PR post COVID-19 Predictions for the public relations industry 2020 South African PR industry Public relations after Coronavirus

Read the original:

The evolution of PR post COVID-19 Marketing News - Media Update

The PNC Financial Services Group, Inc. (PNC) is priced at $106.67 after the most recent trading session. At the very opening of the session, the stock price was $107.67 and reached a high price of $108.47, prior to closing the session it reached the value of $110.99. The stock touched a low price of $105.17.

The PNC Financial Services Group, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $161.79 on 12/30/19, with the lowest value was $79.41 for the same time period, recorded on 03/23/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, The PNC Financial Services Group, Inc. shares are logging -34.07% during the 52-week period from high price, and 34.33% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $79.41 and $161.79.

The companys shares, operating in the sector of financial managed to top a trading volume set approximately around 2.1 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the The PNC Financial Services Group, Inc. (PNC) recorded performance in the market was -33.18%, having the revenues showcasing -29.34% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 45.49B, as it employees total of 50017 workers.

During the last month, 10 analysts gave the The PNC Financial Services Group, Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 12 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 130.98, with a change in the price was noted -45.53. In a similar fashion, The PNC Financial Services Group, Inc. posted a movement of -29.91% for the period of last 100 days, recording 2,726,800 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for PNC is recording 0.89 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.89.

Raw Stochastic average of The PNC Financial Services Group, Inc. in the period of last 50 days is set at 36.09%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 78.43%. In the last 20 days, the companys Stochastic %K was 84.74% and its Stochastic %D was recorded 86.07%.

Considering, the past performance of The PNC Financial Services Group, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -33.18%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -28.07%, alongside a downfall of -21.11% for the period of the last 12 months. The shares increased approximately by 1.21% in the 7-day charts and went down by 7.28% in the period of the last 30 days. Common stock shares were lifted by -29.34% during last recorded quarter.

Read the original post:

The PNC Financial Services Group, Inc. (PNC) is primed for evolution with the beta value of 1.26 - The InvestChronicle

The coronavirus revealed how many companies were unprepared for a pandemic, and remote working has become more important than ever. How can businesses prepare for another disruption?

First of all, having the infrastructure to support collaborative and video conferencing capabilities will be essential. This is particularly important as in the future, remote working will become a bigger part of the workforce and companies will need to be able to meet the needs of workers who continue to do so. On-site server-based video conferencing is limited to specific conference rooms, so moving towards cloud-based solutions is a good first step in supporting remote workers.

Physical meeting rooms will also need to be rethought as physical distancing requirements will likely be in place for the time being. Including stricter cleaning measures in shared spaces and encouraging workers to keep their distance from each other.

The Latest NewsDelivered To Your Inbox

Managing a secure workplace when remote working is also important. Cloud-based systems are the most convenient tools for these workers, but they can also pose security risks. This means companies will need to use powerful VPN services, encrypting files, using secure communication channels and implementing guidelines for physical computer security.

The impact of our current situation is going to change how we work forever, so it is up to companies to prepare for future pandemics and the changing workforce.

Originally posted here:

How Companies Should Prepare For The Evolution Of Work - ABCN's Officing Today

ABM Industries Incorporated (ABM) is priced at $34.49 after the most recent trading session. At the very opening of the session, the stock price was $35 and reached a high price of $35.74, prior to closing the session it reached the value of $35.95. The stock touched a low price of $34.26.

ABM Industries Incorporated had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $42.67 on 08/01/19, with the lowest value was $19.79 for the same time period, recorded on 03/24/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, ABM Industries Incorporated shares are logging -19.17% during the 52-week period from high price, and 74.27% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $19.79 and $42.67.

The companys shares, operating in the sector of services managed to top a trading volume set approximately around 1.43 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the ABM Industries Incorporated (ABM) recorded performance in the market was -8.54%, having the revenues showcasing -11.29% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 2.31B, as it employees total of 140000 workers.

During the last month, 4 analysts gave the ABM Industries Incorporated a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 34.11, with a change in the price was noted -3.17. In a similar fashion, ABM Industries Incorporated posted a movement of -8.42% for the period of last 100 days, recording 484,330 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for ABM is recording 0.55 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.51.

Raw Stochastic average of ABM Industries Incorporated in the period of last 50 days is set at 75.69%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 85.86%. In the last 20 days, the companys Stochastic %K was 92.95% and its Stochastic %D was recorded 94.01%.

Lets take a glance in the erstwhile performances of ABM Industries Incorporated, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -8.54%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -7.71%, alongside a downfall of -5.84% for the period of the last 12 months. The shares increased approximately by 4.44% in the 7-day charts and went down by 10.72% in the period of the last 30 days. Common stock shares were lifted by -11.29% during last recorded quarter.

Read more from the original source:

ABM Industries Incorporated (ABM) is primed for evolution with the beta value of 1.11 - The InvestChronicle

Gilead Sciences, Inc. (GILD) is priced at $84.00 after the most recent trading session. At the very opening of the session, the stock price was $85.47 and reached a high price of $85.67, prior to closing the session it reached the value of $83.14. The stock touched a low price of $81.33.

Gilead Sciences, Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the companys stock is recorded $85.97 on 03/19/20, with the lowest value was $60.89 for the same time period, recorded on 10/03/19.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Gilead Sciences, Inc. shares are logging -2.29% during the 52-week period from high price, and 37.95% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $60.89 and $85.97.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 38.89 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Gilead Sciences, Inc. (GILD) recorded performance in the market was 29.27%, having the revenues showcasing 31.19% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 110.56B, as it employees total of 11800 workers.

During the last month, 11 analysts gave the Gilead Sciences, Inc. a BUY rating, 2 of the polled analysts branded the stock as an OVERWEIGHT, 12 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 3 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 70.53, with a change in the price was noted +18.07. In a similar fashion, Gilead Sciences, Inc. posted a movement of +27.41% for the period of last 100 days, recording 19,211,229 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for GILD is recording 1.09 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.98.

Raw Stochastic average of Gilead Sciences, Inc. in the period of last 50 days is set at 90.86%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 87.58%. In the last 20 days, the companys Stochastic %K was 73.26% and its Stochastic %D was recorded 64.24%.

If we look into the earlier routines of Gilead Sciences, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 29.27%. Additionally, trading for the stock in the period of the last six months notably improved by 32.39%, alongside a boost of 29.49% for the period of the last 12 months. The shares increased approximately by 1.80% in the 7-day charts and went down by 8.00% in the period of the last 30 days. Common stock shares were driven by 31.19% during last recorded quarter.

Read more:

Gilead Sciences, Inc. (GILD) is primed for evolution with the beta value of 0.71 - The InvestChronicle

Lets start up with the current stock price of Fastenal Company (FAST), which is $36.22 to be very precise. The Stock rose vividly during the last session to $36.64 after opening rate of $36.47 while the lowest price it went was recorded $35.88 before closing at $36.74.

Fastenal Company had a pretty favorable run when it comes to the market performance. The 1-year high price for the companys stock is recorded $39.31 on 02/20/20, with the lowest value was $26.72 for the same time period, recorded on 03/23/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Fastenal Company shares are logging -7.85% during the 52-week period from high price, and 35.58% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $26.72 and $39.31.

The companys shares, operating in the sector of services managed to top a trading volume set approximately around 5.49 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Fastenal Company (FAST) recorded performance in the market was -1.98%, having the revenues showcasing 0.22% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 20.70B, as it employees total of 22131 workers.

During the last month, 2 analysts gave the Fastenal Company a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 11 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 1 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 35.25, with a change in the price was noted +0.94. In a similar fashion, Fastenal Company posted a movement of +2.66% for the period of last 100 days, recording 5,133,671 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for FAST is recording 0.17 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.17.

Raw Stochastic average of Fastenal Company in the period of last 50 days is set at 75.50%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 78.03%. In the last 20 days, the companys Stochastic %K was 83.40% and its Stochastic %D was recorded 87.85%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -1.98%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -1.39%, alongside a boost of 4.58% for the period of the last 12 months. The shares increased approximately by 4.53% in the 7-day charts and went down by 3.72% in the period of the last 30 days. Common stock shares were driven by 0.22% during last recorded quarter.

Continue reading here:

Fastenal Company (FAST) is primed for evolution with the beta value of 1.14 - The InvestChronicle

CymaBay Therapeutics, Inc. (CBAY) is priced at $1.80 after the most recent trading session. At the very opening of the session, the stock price was $1.83 and reached a high price of $1.9, prior to closing the session it reached the value of $1.82. The stock touched a low price of $1.8.

CymaBay Therapeutics, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $13.55 on 05/15/19, with the lowest value was $1.21 for the same time period, recorded on 03/18/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, CymaBay Therapeutics, Inc. shares are logging -86.68% during the 52-week period from high price, and 49.17% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $1.21 and $13.55.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 528432 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the CymaBay Therapeutics, Inc. (CBAY) recorded performance in the market was -7.14%, having the revenues showcasing -2.15% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 122.96M, as it employees total of 24 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.7011, with a change in the price was noted +0.1800. In a similar fashion, CymaBay Therapeutics, Inc. posted a movement of +10.84% for the period of last 100 days, recording 1,546,513 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for CBAY is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of CymaBay Therapeutics, Inc. in the period of last 50 days is set at 91.30%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 88.46%. In the last 20 days, the companys Stochastic %K was 94.64% and its Stochastic %D was recorded 92.16%.

Bearing in mind the latest performance of CymaBay Therapeutics, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -7.14%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -59.91%, alongside a downfall of -85.79% for the period of the last 12 months. The shares increased approximately by 12.54% in the 7-day charts and went down by 15.92% in the period of the last 30 days. Common stock shares were lifted by -2.15% during last recorded quarter.

Read this article:

CymaBay Therapeutics, Inc. (CBAY) is primed for evolution with the beta value of 1.03 - The InvestChronicle

Evidence is mounting that the killer coronavirus has already mutated into dozens of new strains, but the dire warnings of scientists appear to be falling, yet again, on the deaf ears of those coordinating the pandemic.Several studies have confirmed the mutation phenomenon is a reality for the Wuhan virus but the World Health Organization appears to be unwilling to draw conclusions from these early studies.The official line is still: there is no evidence that the virus has been changing.Viruses are incredibly complex, especially the novel variety, so caution is understandable.A virus is neither alive nor dead and it continues existing through a process of replication which inevitably becomes error-ridden.Those mistakes in genetic sequencing become mutations.This is a function of existence which is both unavoidable and the very reason species evolve.It is simply untrue to suggest that there is no evidence the virus has been changing and the WHOs stance has been puzzling to scientists who study viruses and understand how they evolve.According to epidemiologist Erik Volz at Imperial College London, all viruses mutate and COVID-19 is no exception.I think its a fact that there are two strains, he said.Its normal for viruses to undergo evolution when they are transmitted to a new host.University of Reading biomedical scientist Ian Jones reveals a virus mutates half a dozen times each time it replicates in its victims respiratory tract.There is plenty of evidence the virus is changing but the WHO is reluctant to accept this well-documented scientific fact.And why does it matter?Different strains can vastly change the direction of this pandemic. Strains can be more aggressive, contain a more potent viral load, as scientists describe it, and even target specific demographics more ferociously.All of which could have vast implications for isolation policies such as the effectiveness of herd immunity or the need for people with certain medical conditions to isolate for longer periods of time.Researchers in India believe they have discovered evidence of at least 10 different strains.National Institute of Biomedical Genomics researcher Partha Majumder believes the Wuhan virus started off as an ancestral O-type strain before splitting off into several other versions.That original strain, now dubbed SARS-CoV2, appeared to be a bolstered version of the old SARS virus which had muted to have better transmission rates.To live, a virus must propagate by infecting other animals, he wrote.A mutation usually disables the virus from transmitting itself.However, some mutations enable the virus to transmit more efficiently and infect more persons.Such mutant viruses increase the frequency of transmission and sometimes completely replace the original type of the virus. The SARS-CoV2 is doing just that."Concerningly one strain, A2a, accounted for nearly half of test samples making it the most dominant strain the Indian team encountered.As scientists from different fields begin to pool their experiences with the virus it is becoming clearer that specific demographics are more at risk to the mutated strains.Obesity and age appear to be the largest and most obvious risk factors, but it has emerged that at least some strains of the Wuhan virus are triggering stokes in people outside of those demographic confines.Researchers at the New England Journal of Medicine are probing the deaths of five coronavirus patients, all aged under 50, who suffered large vessel strokes in a two week period.Of the five, one patient died, one is in intensive care and three are in post-stroke recovery.The concern for researchers were the near-complete lack of symptoms for all individuals.It appears that one strain of the coronavirus targets large blood vessels in a manner similar to what happened with the first SARS outbreak.Moreover, large-vessel stroke was reported in association with the 2004 SARS-CoV-1 outbreak in Singapore, the researchers wrote.Coagulopathy and vascular endothelial dysfunction have been proposed as complications of Covid-19.3 The association between large-vessel stroke and Covid-19 in young patients requires further investigation.It is disappointing that senior health officials at the WHO have failed to address any of the above concerns.While the scientific community does not share consensus issuing absolutist statements suggesting the virus cannot mutate, or cannot be transmitted from person to person, is dangerous and could have very deadly consequences.As more is learned about the Wuhan virus the real experts must be brought into the conversation and our leaders must be cautious about taking advice from an organisation which has got so much wrong.

See original here:

COVID 2.0: The deadly evolution of misinformation - Sky News Australia

Omnicom Group Inc. (OMC) is priced at $55.87 after the most recent trading session. At the very opening of the session, the stock price was $56.02 and reached a high price of $56.32, prior to closing the session it reached the value of $57.03. The stock touched a low price of $55.01.

Omnicom Group Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $85.05 on 07/16/19, with the lowest value was $46.37 for the same time period, recorded on 03/23/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Omnicom Group Inc. shares are logging -34.31% during the 52-week period from high price, and 20.49% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $46.37 and $85.05.

The companys shares, operating in the sector of services managed to top a trading volume set approximately around 851928 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Omnicom Group Inc. (OMC) recorded performance in the market was -29.61%, having the revenues showcasing -24.95% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 12.45B, as it employees total of 70000 workers.

During the last month, 3 analysts gave the Omnicom Group Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 3 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 68.82, with a change in the price was noted -23.89. In a similar fashion, Omnicom Group Inc. posted a movement of -29.88% for the period of last 100 days, recording 2,415,393 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for OMC is recording 1.85 at the time of this writing. In addition, long term Debt to Equity ratio is set at 1.62.

Raw Stochastic average of Omnicom Group Inc. in the period of last 50 days is set at 30.09%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 50.27%. In the last 20 days, the companys Stochastic %K was 66.23% and its Stochastic %D was recorded 74.33%.

Lets take a glance in the erstwhile performances of Omnicom Group Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -29.61%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -26.12%, alongside a downfall of -27.78% for the period of the last 12 months. The shares increased approximately by 9.37% in the 7-day charts and went up by 10.76% in the period of the last 30 days. Common stock shares were lifted by -24.95% during last recorded quarter.

View original post here:

Omnicom Group Inc. (OMC) is primed for evolution with the beta value of 0.73 - The InvestChronicle

Lets start up with the current stock price of Genius Brands International, Inc. (GNUS), which is $0.32 to be very precise. The Stock rose vividly during the last session to $0.34 after opening rate of $0.31 while the lowest price it went was recorded $0.31 before closing at $0.30.

Genius Brands International, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $2.33 on 05/08/19, with the lowest value was $0.05 for the same time period, recorded on 03/12/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Genius Brands International, Inc. shares are logging -86.27% during the 52-week period from high price, and 520.16% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $0.05 and $2.33.

The companys shares, operating in the sector of services managed to top a trading volume set approximately around 1.61 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Genius Brands International, Inc. (GNUS) recorded performance in the market was 9.68%, having the revenues showcasing -7.23% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 8.68M, as it employees total of 19 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.2823, with a change in the price was noted +0.0282. In a similar fashion, Genius Brands International, Inc. posted a movement of +9.42% for the period of last 100 days, recording 718,849 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for GNUS is recording 0.60 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.34.

Raw Stochastic average of Genius Brands International, Inc. in the period of last 50 days is set at 69.25%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 75.63%. In the last 20 days, the companys Stochastic %K was 61.86% and its Stochastic %D was recorded 54.88%.

Considering, the past performance of Genius Brands International, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 9.68%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -56.37%, alongside a downfall of -84.66% for the period of the last 12 months. The shares increased approximately by 0.28% in the 7-day charts and went up by 14.03% in the period of the last 30 days. Common stock shares were lifted by -7.23% during last recorded quarter.

Here is the original post:

Genius Brands International, Inc. (GNUS) is primed for evolution with the beta value of 0.20 - The InvestChronicle

Ferro Corporation (FOE) is priced at $10.48 after the most recent trading session. At the very opening of the session, the stock price was $10.23 and reached a high price of $10.73, prior to closing the session it reached the value of $9.78. The stock touched a low price of $10.2.

Ferro Corporation had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $18.03 on 04/30/19, with the lowest value was $7.52 for the same time period, recorded on 04/03/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Ferro Corporation shares are logging -41.89% during the 52-week period from high price, and 39.36% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $7.52 and $18.03.

The companys shares, operating in the sector of basic materials managed to top a trading volume set approximately around 1.24 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Ferro Corporation (FOE) recorded performance in the market was -29.33%, having the revenues showcasing -25.88% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 860.23M, as it employees total of 5922 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 12.36, with a change in the price was noted -3.99. In a similar fashion, Ferro Corporation posted a movement of -27.57% for the period of last 100 days, recording 864,183 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for FOE is recording 2.24 at the time of this writing. In addition, long term Debt to Equity ratio is set at 2.22.

Raw Stochastic average of Ferro Corporation in the period of last 50 days is set at 39.78%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 92.07%. In the last 20 days, the companys Stochastic %K was 78.32% and its Stochastic %D was recorded 66.57%.

Lets take a glance in the erstwhile performances of Ferro Corporation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -29.33%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -8.87%, alongside a downfall of -41.35% for the period of the last 12 months. The shares increased approximately by 10.94% in the 7-day charts and went up by 17.36% in the period of the last 30 days. Common stock shares were lifted by -25.88% during last recorded quarter.

Here is the original post:

Ferro Corporation (FOE) is primed for evolution with the beta value of 1.82 - The InvestChronicle

Lets start up with the current stock price of Xenia Hotels & Resorts, Inc. (XHR), which is $10.22 to be very precise. The Stock rose vividly during the last session to $10.51 after opening rate of $9.87 while the lowest price it went was recorded $9.87 before closing at $9.46.

Xenia Hotels & Resorts, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $23.33 on 05/06/19, with the lowest value was $6.28 for the same time period, recorded on 03/19/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Xenia Hotels & Resorts, Inc. shares are logging -56.19% during the 52-week period from high price, and 62.74% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $6.28 and $23.33.

The companys shares, operating in the sector of financial managed to top a trading volume set approximately around 1.08 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Xenia Hotels & Resorts, Inc. (XHR) recorded performance in the market was -52.71%, having the revenues showcasing -47.46% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.15B, as it employees total of 48 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 15.98, with a change in the price was noted -10.57. In a similar fashion, Xenia Hotels & Resorts, Inc. posted a movement of -50.84% for the period of last 100 days, recording 900,517 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for XHR is recording 0.74 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.74.

Raw Stochastic average of Xenia Hotels & Resorts, Inc. in the period of last 50 days is set at 30.05%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 83.97%. In the last 20 days, the companys Stochastic %K was 57.26% and its Stochastic %D was recorded 36.86%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -52.71%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -51.03%, alongside a downfall of -52.79% for the period of the last 12 months. The shares increased approximately by 2.50% in the 7-day charts and went up by 24.48% in the period of the last 30 days. Common stock shares were lifted by -47.46% during last recorded quarter.

See original here:

Xenia Hotels & Resorts, Inc. (XHR) is primed for evolution with the beta value of 1.18 - The InvestChronicle

Lets start up with the current stock price of Seelos Therapeutics, Inc. (SEEL), which is $0.59 to be very precise. The Stock rose vividly during the last session to $0.61 after opening rate of $0.54 while the lowest price it went was recorded $0.54 before closing at $0.53.

Seelos Therapeutics, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $3.06 on 04/30/19, with the lowest value was $0.42 for the same time period, recorded on 04/02/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Seelos Therapeutics, Inc. shares are logging -80.67% during the 52-week period from high price, and 41.00% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $0.42 and $3.06.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.32 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Seelos Therapeutics, Inc. (SEEL) recorded performance in the market was -55.86%, having the revenues showcasing -49.01% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 25.56M, as it employees total of 6 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.9309, with a change in the price was noted -0.3505. In a similar fashion, Seelos Therapeutics, Inc. posted a movement of -37.21% for the period of last 100 days, recording 784,184 in trading volumes.

Raw Stochastic average of Seelos Therapeutics, Inc. in the period of last 50 days is set at 22.92%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 90.29%. In the last 20 days, the companys Stochastic %K was 83.13% and its Stochastic %D was recorded 72.72%.

Considering, the past performance of Seelos Therapeutics, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -55.86%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -34.39%, alongside a downfall of -80.35% for the period of the last 12 months. The shares increased approximately by 1.40% in the 7-day charts and went up by 25.85% in the period of the last 30 days. Common stock shares were lifted by -49.01% during last recorded quarter.

Continue reading here:

Seelos Therapeutics, Inc. (SEEL) is primed for evolution with the beta value of 1.14 - The InvestChronicle

The Idea of the BrainMatthew CobbBasic Books, $32

Neuroscientistslove a good metaphor. Through the years, plumbing, telegraph wires and computershave all been enlisted to help explain how the brain operates, neurobiologistand historian Matthew Cobb writes in The Idea of the Brain. And like anymetaphor, those approximations all fall short.

Cobb leads afascinating tour of how concepts of the brain have morphed over time. Hiswriting is clear, thoughtful and, when called for, funny. He describesexperiments by neurosurgeon Wilder Penfield, who zapped awake patients brainswith electricity to provoke reactions. Zapping certain places consistentlydredged up memories, which Cobb calls oneiric experiences. His footnote onthe term: Look it up. Its exactly theright word. I did, and it was.

Cobb runs though the history of certain concepts used to explain how the brain works, including electricity, evolution andneurons. Next comes a section on the present, which includes discussions ofmemory, circuits and consciousness. Cobb offers tastes of the latest research, anda heavy dose of realism. Memory studieshave made progress, but we are still far from understanding what ishappening when we remember, Cobb writes. Despite big efforts, we still onlydimly understand what is going on when we see.Our understanding of how antidepressants work? Virtually non-existent.

Headlines and summaries of the latest Science News articles, delivered to your inbox

This real talk isrefreshing, and Cobb uses it to great effect toargue that neuroscience is stymied. There have been many similarmoments in the past, when brain researchers became uncertain about how toproceed, he writes. Scientists have amassed an impressive stockpile of brain facts,but a true understanding of how the brain works eludes us.

Dont expect a computer metaphor to help. Like a computer, the brainsmain job is to process information. But some experts argue that because brains are biologicalthey evolved within the vagaries of a bodythey operate in ways that a machine doesnt (SN: 8/23/16).

Cobb reckonsthat, among other reasons, the mere existenceof such objections is a harbinger of the end of the computer metaphor.But that doesnt mean the comparison was awaste. Metaphors clarify thoughts, he writes, and scientists would do well toponder what might replace the concept.

He ends the book with a creative exercise inlooking ahead to what the future might hold. The possibilities include the creation of conscious machines, or even having toaccept that there is no brain theory to be found. Still, our currentignorance should not be viewed as a sign of defeat, Cobb writes, but as achallenge.

Buy The Idea of the Brain from Amazon.com.Science Newsis a participant in the Amazon Services LLC Associates Program. Please see ourFAQfor more details.

See the original post here:

The Idea of the Brain explores the evolution of neuroscience - Science News

Extraction comes from the Russos production company AGBO, and is its second feature following last falls 21 Bridges (2019), starring Chadwick Boseman. So far, the Russos have primarily used the film side of AGBO as a chance to develop non-superhero stories with a troupe of MCU actors. With the exception of the upcoming Sundance horror hit, Relic, also produced by Jake Gyllenhaal, AGBO has placed its development attention on mid-budget action thrillers, a source of lifeblood for theatrical experiences before the superhero boom of the 2000s. The production companys next film, Cherry, also directed by the Russo Brothers, stars Tom Holland as a bank robber with an opioid addiction. AGBO also has a remake of The Thomas Crown Affair on the docket, and it wouldnt come as a surprise to see a Marvel star at the front of that film as well. There is an interest at the production company, it would seem, in finding a new way to take these superhero actors who possess the kind of star power that would have made them bigger than any one character in the '90s, and pair them with old-school premises, all for a reasonable price.

Extraction revels in the kind of old-school action of the '90s, boasting crazy stunts and a surplus of gunplay. While the plot is reminiscent of Man on Fire (1987) and (2004), and Hargraves direction is sure to draw fair comparisons to the John Wick franchise, Extraction is even simpler than that. It eschews world building of the Keanu Reeves franchise for the kind of pure action movie spectacle that those raised on the films of Stallone and Schwarzenegger might expect. But Hemsworth is different from the leading men of old, and even while placed within a story that feels like a throwback, his performance is uniquely modern in terms of our expectations of the action lead. Hemsworths mercenary, Tyler Rake, isnt entirely unlike characters weve seen before, men with military backgrounds and tragic pasts who are forced to serve as both protector and caretaker. But whereas so many of these types of characters begin as emotionally detached at best, and assholes at worst, Rake is likable without trying to come across as so. Theres an inherent charisma to the character, and his relationship with 14-year-old Ovi (Rudhraksh Jaiswal), while not close initially, isnt without some sense of kinship, manifested in Rakes early referral to him as mate and his consideration of him as more than a package but a person. Whats interesting about Hemsworths performance here is that the role of Tyler Rake is not so different from the kind of roles he was offered at the start of his career. Yet, his filmography has given him the tools to transform his inherent good looks and stoicism into something more compelling and worthy of the star power he now possesses.

Its easy to imagine seeing Extraction in theaters, as the film certainly looks theatrical, and features action and set pieces that would look incredible on a big screen. But the film stands to get more eyes on it on Netflix than it would in the theatrical marketplace, and this would have been true before the COVID-19 pandemic. Boasting a strong performance from Boseman,21 Bridges, a weaker film than Extraction, made $50 million on a $33 million budget. Not a big loss for STXFilms, but its a prime example of a film that would have undoubtedly found a larger audience and served Bosemans star power better on Netflix. As we see cinemas become increasingly event-driven, with audiences more willing to shell out for ticket prices only for the biggest films, it becomes harder for actors to attract general audiences for anything beyond the superheroes they play. Just because everyone turned out to see Boseman as Black Panther, doesnt mean that theyll do the same to see him play an NYC cop. But with streaming services, and nonevent level expectations that come with those releases, actors have a better chance to see their star power utilized in the same way those marquee names of the '90s did. While "lets watch the new Thor" is far more likely to be heard than "lets watch the new Hemsworth" at cinemas, the latter statement is far more likely when considering the age of streaming.

Hemsworth is the perfect example through which to consider the wane of traditional star power and its newfound potential. Before landing the career-changing role of Thor in Kenneth Branaghs 2011 film, Hemsworths filmography consisted of a brief role as George Kirk in Star Trek (2009), and small supporting roles in horror movies A Perfect Getaway (2009) and The Cabin in the Woods (2011), which showed early range but didnt necessarily suggest a leading man. Thor and The Avengers, gave him weightier material, including a powerful scene that saw him face off against Anthony Hopkins, but the takeaway from those performances resulted mostly in roles that did little to set him apart from Hollywood's then-current crop of blond leading men. Red Dawn (2012) and Snow White and the Huntsman (2012) were the most immediate signs that Hemsworth's portrayal of a superhero didnt automatically result in a box office following. Snow White was a box office success, but as the sequel, The Huntsman: Winters War, eventually proved, the success of the first had more to do with an attachment to the fairy tale, and a great trailer, than any real interest in Hemsworth as a YA romance styled sword and sorcery hero.

The most important step in Hemsworths post-Thor career was playing James Hunt in Ron Howards Rush (2013). Not entirely a 180 from Thor, Hemsworths charm and swagger, fully on display here, also manifested something deeper, a steely-eyed focus that suggested not only a grand inner monologue but a stormy emotionality. Theres a sense of drive in Hemsworths performance as Hunt, a conscious desire to cover up a formidable and dangerous feeling of inferiority. Further performances in Michael Manns Blackhat (2015) and Howards In the Heart of the Sea (2015), neither critical or box office darlings, showcased the potential of an actor who never seemed quite comfortable in the role of jock or eye candy. In terms of the latter, Hemsworth managed to push against this type of casting and poke fun at himself by entering the realm of comedy, first with Vacation (2015), and then with Ghostbusters (2016). Again, neither film was a critical or box office success, despite Hemsworth being genuinely funny, but they sharpened the tools that took him to his next venture, and allowed him to bring more of himself and comedy to Thor by the time he reached the third entry,Thor: Ragnarok (2017), which revitalized his interest in the role.

Hemsworth tapped into his dark side as a charismatic cult leader, Billy Lee, in the criminally underseen Bad Times at the El Royale (2019), arguably his best performance, and channeled Roger Moore in Men in Black: International. Whats interesting about his career is that despite very little box office success outside of his role as Thor, Hemsworth shows the most consistent evolution as a performer of his Avengers co-stars. Theres never a sense that hes simply settled into the comfort of being an actor known for one type of role, even if he does find himself appearing in some genres more frequently than others. Theres a quality to Hemsworth that makes him comparable to fellow Aussie Mel Gibson, before his directorial fame with Braveheart (1995), and the controversies that have marred the latter part of his career. Theres a quality the two actors share, not only because they both found their fame in franchises, Thor and Mad Max, but because they also managed to deliver engaging, genre-crossing performances in films that werent box office sensations but showed a consistent development of craft. Most important, Hemsworth, like Gibson, is an action hero whose tears are believable. It may seem like a small thing, but theres a vulnerability to Hemsworth that allows him to come across as genuine and personable, an essential quality when so much of action films are built around artifice and grandeur. His ability to convincingly play the vulnerable hero made him the MVP of Infinity War, and its what allows for the investment in Extraction. Tyler Rake is a role Hemsworth could have been cast in immediately after Thor, but he wouldnt be nearly as effective as he is in it without the decade of refinement.

Star power will likely never translate into box office receipts the way it used to, but that doesnt mean the concept is gone. It seems likely that it will simply translate into a new format. While Netflix is typically hush hush on how its features perform, it wouldn't be a surprise to see the streaming service champion the film as one of its biggest hits, especially with households craving new content while under quarantine. Turning star power into streaming service currency seems like a realistic outcome not only for AGBO, which has yet to finalize a distributor for Cherry, but for a number of studios still looking to keep mid-budget films alive, and agents who still bet on the power of a name. Extraction isnt the first of Netflixs big-budget releases, which include Six Underground (2019) and Bright (2017), but it is arguably the best, and the best argument for selling films based on names. Chris Hemsworth may not get his name on theater marquees for opening days, but his name is certainly going to populate a lot of Netflix queues over the weekend.

View post:

'Extraction' and the Evolution of Chris Hemsworth - Hollywood Reporter

By Grant Sharples

Paramore, despite no longer making pop-punk music, have become one of the quintessential bands in the genre. Their early catchy, cathartic choruses on songs such as crushcrushcrush and Thats What You Get are representative of the entire Warped-Tour era of the 2000s. But although this heavily male-dominated, often misogynistic scene consisted of plenty of bands wishing for their ex-girlfriends deaths amid other violent fantasies, Paramore defied its patriarchal penchant.

Ringleader Hayley Williams has reckoned with her own share of internalized misogyny and eventually decided to stop performing Misery Business live because of its infamous lyric Once a whore, youre nothing more. She has brought that critical self-analysis to her own solo career, which shes spent 2020 rolling out across both music and visuals.

When record executives wanted to make Williams a solo artist at age 14, she refused and started a pop-punk band instead. Unlike the catalogs of many of her bands peers, each entry in Paramores discography has expanded upon and differentiated itself from what preceded it, evolving from hard guitars to more mature motifs and eventually an 80s synth-pop sound. Now, with the impending release of Williamss debut solo album, Petals for Armor, she has evolved yet again, showing a propensity for minimalist indie-pop with hints of funk, folk, and, of course, emo. Williams has been somewhat of a musical chameleon, constantly shapeshifting and adopting new sounds, mastering one only to abandon it and try another.

Though Petals for Armor is due out in full May 8, Williams has preceded it with two exploratory EPs. The 10 songs released so far and what came before them showcase how far shes come in the past 15 years.

Read the rest here:

Hayley Williams' Evolution From Paramore To 'Petals For Armor' - MTV.com

BMW's kidney grille is such a distinctive design element of the brand's models that it's hard to picture a product from the company without these dual openings at the front. It's now an iconic element for the firm's styling.

The famous design detail has changed many times since 1933, and it has only become bigger and bigger in recent years. Just look at the forthcoming BMW 4 Series for the best example.

But where does the BMW "double kidney" come from and how has it evolved over the years? Let's find out together!

A brief historical note is necessary because when the BMW 303 was born in 1933, the double kidney was nothing more than a radiator grille divided into two long vertical parts that angled rearwards on the outside.

Designer Fritz Fielder used this split design as a way to improve the 303's aerodynamics. His decision kicked off a legend that has continued to appear on BMW's machine. Over time, the iconic grille has changed in height, width, shape, and position, but those who see it know at a glance that the car is a BMW.

The BMW 328 was among the cars that first made the BMW brand (and its grille) known in Europe because of its success in racing.

The style became more famous on the luxurious 327, and the look remained largely intact through the 1940s. In the postwar period, there were the 501 and 502 models that reproduced kidneys with a few changes. On the 503, things started to change when the shape shrunk in height.

In 1956, the 507 brought a complete revolution to the kidney grille. The spectacular sports car with a design by Albrecht von Goertz boasted a pair of short, yet wide horizontal opening that created an integral part of the styling between the headlights.

TheBMW Z8 with a design by Henrik Fisker underthe supervision of Chris Bangle brought the 507's styling back with a more modern appearance. The similarities are obvious, yet don't go so far to make the Z8 look too retro.

In recent years, BMW's designers have tweaked the design to incorporate a horizontal line joining the headlights to the grille. You can see this element on the latest3 Series, 5 Series, and 8 Series. The i3 adapts this look into a smaller size because it does not need air to flow to the engine. With the i8 and latest Z4, the firm stretched the shape to occupy a larger horizontal area of the front end.

The 2011 BMW Vision ConnectedDrive and 2019 BMW Vision M NEXT concepts follow this same general style. However, the designers put a focus on creating more complex polygonal shapes along the edges.

Returning to the earlier evolution of the kidneys, check out look the arrival of the so-called Neue Klasse models in the early 1960s. On these vehicles, the designers used two relatively skinny ovals in the center and incorporated a wide array of mesh outward to the headlights.

The first 5 Series from 1972, the 1975 3 Series, and the 1977 7 Seriesfurther crystallized this distinctive aspect of BMW's frontal design for the decades to come.The general concept of this styling cue lasted until the mid-1990s on some of the brand's machines.

Even while the company's major models wore the trademark combination of a wide grille opening and circular headlights, other products showed experimentation with something different. Vehicles like the M1, Z1, and original 8 Series still had kidneys, but they were smaller and simpler than other members of the lineup.

The 1989 Z1 and 1990 8 Series actually previewed the future direction for the kidneys that later models adopted. In the 1990s, vehicles like the E36-generation 3 Series, E39-gen 5 Series, and much of the rest lineup no longer head the wide grille from the past decades. Instead, the kidneys were a discreet element of the nose, and body-color elements surrounded them.

This styling cue continued into the 2000s on vehicles like the 1 Series, 6 Series, X1, and X3.

Over the past ten years, BMW teased the motoring world by showing concepts and even some production cars with an slightly evolved take on the kidney grille.

With the 2018 BMW X5, the designers enlarged the openings horizontally and vertically. Using chrome for the uprights made them even more visually distinctive. So far, the 2019 7 Series and X7 are the most obvious expressions of this styling cue, but we know that more models like this are on the way.

Before that, however, there was the 2013 BMW Pininfarina Gran Lusso Coupe Concept and the 2014BMW Vision Future Luxury were hints of what was to come.

In 2011, the BMW 328 Hommage concept debuted showing a modern take on the classic model. Part of its design was a large, vertical grille that ran from the tip of the hood nearly to the ground. With the upcoming 4 Series, we are seeing the company incorporate this cue into a production vehicle.

The 2014 BMW 3.0 CSL Hommage, followed by the 2016 Vision Next 100, 2019 Concept 4, and2020 Concept i4highlighted the slow evolution of BMW designers incorporating the taller kidney grille into increasingly production-ready-looking vehicles. We now know the Concept 4 is a very close preview of what to expect from the next-gen 4 Series when it arrives in showrooms.

Even earlier, there were signs of BMW eliminating the gap between the kidneys and using a single bar between them instead. Vehicles like the 2017 Vision Dynamics,2017 Vision iNEXT and 2018 Concept iX3 showed this evolution.

While they are uncommon, there are BMWs without a kidney grille. The Isetta comes to mind, although it's styling originally comes from an Italian microcar. There's also the BMW 700 that has a rear-engine layout, so the kidneys aren't a styling necessity.

Here's where things get weird because there are vehicles with close relationships to the Bavarian automaker without actually being BMW products that have a kidney grille. First, there'sEisenacher Motorenwerk (or EMW) from the former East Germany. Following World War II, the former BMW factory in Eisenach, Germany, began re-manufacturing pre-war BMW vehicles and later some tweaked versions of these products.

There's also the case of Britain's Bristol Cars in the post-war period. It was able to gain access to BMW technology and even employed BMW 303 designersFritz Fielder to create the Bristol 400 that had a striking styling similarity to pre-war BMW vehicles.

There have also been a few cases of designers wanting to tweak the kidney grille. For example, the Spicup concept (green vehicle below) by Bertone in 1969 opted for an angular shape with rectangular shapes, which wasn't on production BMW vehicles at the time although was somewhat simpler to the later M1. Bertone also created the Garmisch (the beige vehicle below) with a diamond-shaped take on the kidneys.

View original post here:

Check Out The BMW Kidney Grille's Evolution Over 87 Years - Motor1